Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma

Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the efficacy of bortezomib as part of primary therapy for patients with multiple myeloma.Describe the safety of bortezomib and bortezomib-based regimens in patients with previously untreated multiple myeloma.Identify new management options for patients with treatment-naïve multiple myeloma. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com